With reference to the above, Nasdaq Stockholm has decided to delist the ordinary shares, preference shares, class B preference shares and warrants of Oscar Properties Holding AB from Nasdaq ...
LUND, SWEDEN / ACCESSWIRE / November 11, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today announced the publication of CAN10 results in disease models of myocarditis ...
Lundin Gold Inc. (TSX: LUG) (Nasdaq Stockholm: LUG) (OTCQX: LUGDF) ("Lundin Gold" or the "Company") is pleased to announce that its Board of Directors has declared a quarterly cash dividend of US$0.20 ...
BioArctic AB (publ) (NASDAQ: BIOA B) (STOCKHOLM: BIOA B) has presented the design of its proprietary BrainTransporter (BT) platform at the ...
BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) will publish the company's third quarter report for July - September 2024 on Thursday, November 14, 2024, at 08:00 a.m. CET.
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today updated their revenue outlook for Leqembi for their 2024 fiscal year (FY), which runs from April 2024 through March 2025. Eisai now ...
Palvelussamme on juuri nyt häiriö, yritäthän myöhemmin uudelleen. Pahoittelemme aiheutunutta haittaa.
Operating cash flow (OCF) for the third quarter of 2024 was USD 73 million in line with forecast. Full year 2024 OCF guidance is revised to USD 335 to 342 million (assuming Brent USD 70 to 80 per ...
The survey highlights a large, hesitant segment, with nearly 30% of respondents undecided about crypto investments. Gender differences are also evident here: 22% of men aged 18-34 express interest in ...
NewsVoir Bengaluru Karnataka [India] 5 Truecaller the leading global platform for verifying contacts and blocking unwanted ...
Notification of share transaction by Director of Millicom (Tigo) shares Luxembourg, November 8, 2024 – Millicom International Cellular S.A. ("Millicom") announces that, on November 8, 2024, Tomas ...
STOCKHOLM, SE / ACCESSWIRE / November 11, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its interim report for the period January - Septem ...